Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Respiratory Medicine

Journal Scan / Research · May 14, 2022

Evaluating the Safety and Efficacy of the Bronchodilator Navafenterol for Treatment of COPD

The European Respiratory Journal


Additional Info

The European Respiratory Journal
The novel bronchodilator navafenterol: a phase 2a, multicentre, randomised, double-blind, placebo-controlled crossover trial in COPD
Eur. Respir. J. 2022 Apr 01;59(4)2100972, D Singh, J Beier, C Astbury, MG Belvisi, CA Da Silva, A Jauhiainen, E Jimenez, A Lei, S Necander, JA Smith, U Wählby Hamrén, W Xin, I Psallidas

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading